Triple DMARDs improves functional ability in early rheumatoid arthritis: A Study The results of the tREACH trial presented today at the European League Against Rheumatism Annual Congress (EULAR 2015) Press Conference showed that initial therapy with combination DMARDs significantly improves measures of disease activity and functional ability in patients with early rheumatoid arthritis (RA). These findings suggest that an initial treatment regimen of methotrexate, sulfasalazine and…
GSK at Conferences on
#LUPUS FACTS: Our global survey found #SLE patients often under-report symptoms to their doctors #EULAR2015
Read about 2 new studies presented at EULAR 2016 reporting how genetic profiling could be used to predict if patients with RA will respond to treatment.
Common variable immunodeficiency is a group of disorders in which the immune system cannot make antibodies in response to foreign substances that may cause infection.